Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects.
Fourteen out of 26 patients with invasive bladder cancer were randomly assigned to receive weekly subcutaneous injections of Corynebacterium parvum (CP) in addition to standard treatment. Peripheral blood T lymphocyte percentage, K cell activity, mitogen responsiveness, and monocyte and polymorph leucotaxis were measured at intervals over a period of 1 to 2 years. The only consistent difference between the CP-treatment patients and the controls was a slightly higher level of K cell activity in the former, who, however, fared rather worse than the controls in terms of survival.
D002470:Cell Survival; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte; D002986:Clinical Trials as Topic; D006801:Humans; D007279:Injections, Subcutaneous; D008214:Lymphocytes / Q000276:immunology; D008934:Mitogens / Q000494:pharmacology; D009000:Monocytes / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D011425:Propionibacterium acnes / Q000276:immunology*; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*
D008934:Mitogens